Jump to content

Olaratumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Anypodetos (talk | contribs) at 07:54, 23 April 2016 (Orphan designation isn't approval). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Olaratumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetPDGF-R α
Clinical data
ATC code
  • none
Legal status
Legal status
  • investigational
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6554H10076N1736O2048S40
Molar mass147.2 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Olaratumab is a monoclonal antibody which is being developed by Imclone for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[1]

In February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft tissue sarcoma.[2]

References